News & Media

BioSig Issues Shareholder Update to Highlight Recent Achievements and Ongoing Developments

Westport, CT, Jan. 19, 2023 (GLOBE NEWSWIRE) -- To date, the Company's FDA 510(k)-cleared PURE EP™ System has been used in approximately 3,000 patient cases across the United States The Company has built a robust pipeline of commercial sale prospects and expects multiple closings in first half of 2023 New supporting clinical data to be published BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering…